Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,130.40 -8.86 -0.28%
FTSE 100 6,571.75 -12.42 -0.19%
DAX 9,300.51 -17.31 -0.19%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,696.29 0.28 0.00%

Breakthrough Research that Help Address Complex Diseases and Offer Diverse Treatments - Research Report on Medivation, Jazz,



  Breakthrough Research that Help Address Complex Diseases and Offer Diverse
 Treatments - Research Report on Medivation, Jazz, NPS, Infinity and Halozyme

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, June 27, 2013

NEW YORK, June 27, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting
Medivation, Inc. (NASDAQ: MDVN), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), NPS
Pharmaceuticals, Inc. (NASDAQ: NPSP), Infinity Pharmaceuticals, Inc. (NASDAQ:
INFI) and Halozyme Therapeutics, Inc. (NASDAQ: HALO). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Medivation, Inc. Research Report

On June 24, 2013, Medivation, Inc. (Medivation) and Astellas Pharma Europe
Ltd., (Astellas) announced that the European Commission (EC) granted the
marketing authorization for XTANDI capsules. XTANDI is used for treatment of
adult men with metastatic castration-resistant prostate cancer whose disease
has progressed on or after docetaxel therapy. "This is a major development in
prostate cancer therapeutics that will provide an important new treatment
option for patients with advanced prostate cancer following chemotherapy,"
said Professor Johann de Bono, Professor of Experimental Cancer Medicine at
The Institute of Cancer Research, London, and Consultant Medical Oncologist at
The Royal Marsden NHS Foundation Trust. The Company stated that the European
Commission approval triggers a $15 million milestone payment to Medivation
under its collaboration with Astellas. The Full Research Report on Medivation,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/4e75_MDVN]

--

Jazz Pharmaceuticals plc Research Report

On June 5, 2013, Jazz Pharmaceuticals plc (Jazz) presented data called The
Burden of Narcolepsy Disease (BOND) study at SLEEP 2013, the annual meeting of
the Associated Professional Sleep Societies LLC The study found that patients
with narcolepsy, with or without cataplexy, were more likely to suffer from a
higher frequency of comorbidities such as mental illness, endocrine disorders,
digestive disorders and cardiovascular disease, and had more than twice the
mean annual medical costs compared with the general population. "Jazz
Pharmaceuticals plc continues to support ongoing narcolepsy research, such as
BOND and AWAKEN, and hopes that awareness of the data presented at SLEEP will
help sleep specialists, physicians and the general public better understand
narcolepsy as a serious disabling medical condition," said Jed Black, M.D.,
Vice President, Sleep Medicine, Jazz Pharmaceuticals and Consulting Associate
Professor, Stanford University Medical Center, Stanford Center for Sleep
Sciences and Medicine. The Full Research Report on Jazz Pharmaceuticals plc -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/5ee9_JAZZ]

--

NPS Pharmaceuticals, Inc. Research Report

On June 13, 2013, NPS Pharmaceuticals, Inc. (NPSP) presented initial findings
from PARADOX at ENDO 2013, the Endocrine Society's 95th Annual Meeting in San
Francisco, California. The Company believes that PARADOX is the largest and
the most comprehensive collection of research to date analyzing the burden of
illness for hypoparathyroidism. The Key findings from this analysis of PARADOX
suggest that patients with hypoparathyroidism have a high burden of illness,
as 99% continue to experience multiple symptoms despite the use of calcium and
vitamin D supplements and other medications. Bart Clarke, MD, Associate
Professor of Medicine at the Mayo Clinic in Rochester, MN and lead researcher
for PARADOX said, "Hypoparathyroidism is the only classic endocrine disorder
without an approved replacement therapy and these data reinforce the need for
improved treatment options targeting the underlying cause of the disorder."
The Full Research Report on NPS Pharmaceuticals, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.wsreports.com/r/full_research_report/4519_NPSP]

--

Infinity Pharmaceuticals, Inc. Research Report

On June 24, 2013, Infinity Pharmaceuticals, Inc. (Infinity) announced its
Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of
phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with
advanced hematologic malignancies, or potentially fatal blood cancers. Data
from the study showed that IPI-145 was well tolerated and clinically active
across a broad range of blood cancers, including indolent non-Hodgkin lymphoma
(iNHL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL),
Hodgkin lymphoma (HL) and T-cell lymphomas. "The early Phase 1 data of IPI-145
in patients with iNHL are exciting, and we believe IPI-145 has the potential
to become the best-in-class PI3K inhibitor in this indication," stated Julian
Adams, Ph.D., president of research and development at Infinity. The Full
Research Report on Infinity Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.wsreports.com/r/full_research_report/306c_INFI]

--

Halozyme Therapeutics, Inc. Research Report

On June 3, 2013, Halozyme Therapeutics, Inc. (Halozyme) announced the results
from a Phase 1b trial PEGylated Recombinant Human Hyaluronidase (PEGPH20), an
investigational new biologic, in combination with gemcitabine for the
treatment of patients with stage IV metastatic pancreatic cancer. In this
single-arm Phase 1b trial, the overall response rate by RECIST 1.1 criteria
was 42% for those treated at therapeutic dose levels of PEGPH20, assessed by
an independent radiology review. Lead Investigator Sunil Hingorani, M.D.,
Ph.D., Associate Member of the Clinical Research and Public Health Divisions
at Fred Hutchinson Cancer Research Center said, "Pancreatic cancer is one of
the most challenging cancers to treat. We are encouraged by these early stage
clinical data, and look forward to further testing the potential of PEGPH20 in
randomized trials in combination with the most active regimens available for
patients today." The Full Research Report on Halozyme Therapeutics, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/eb1a_HALO]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement